• Navneet Singh Department of Chemistry, School of Chemical Engineering and Physical Science, Lovely Professional University, Phagwara, Punjab, India.
  • Sazal Patyar Departmentof Pharmaceutical Sciences, School of Pharmaceutical Science, Lovely Professional University, Phagwara, Punjab, India.
  • Naveen Chandra Talniya Department of Chemistry, School of Chemical Engineering and Physical Science, Lovely Professional University, Phagwara, Punjab, India.


 Ascites impairs both the physical and mental dimensions of quality of life in patients. The patients due to unawareness do not report to medical practitioners in the early stage of disease, and also in few cases, medical practitioners due to lack of adequate expertise face difficulty to ensure the early stage detection for causes of ascites, i.e., due to cirrhosis, cancer, congestive heart failure, mycobacterium tuberculosis, or others. Ascites is a symptom of progression of single disease or multiple diseases. Gross collection of fluid in peritoneal cavity may initiate a series of problems such as spontaneous bacterial peritonitis and an increase in abdominal distension and discomfort and hinder the mobility of the patient and dullness and loss of appetite. In the present review, a detail study over the ecology of ascites has been done with emphasizing on diagnosis by history and physical examination, clinical examination, and imagining techniques followed by management of treatment through general guidelines, and various available therapies are covered.

Keywords: Ascites, Malignant, Benign, Imaging techniques, Peritoneal, Ascetic fluid.

Author Biography

Navneet Singh, Department of Chemistry, School of Chemical Engineering and Physical Science, Lovely Professional University, Phagwara, Punjab, India.

Assistant Professor

Department of Chemistry,


1. Thoeni RF. The role of imaging in patients with ascites. AJR Am J Roentgenol 1995;165:16-8.
2. Runyon BA. Care of patients with ascites. N Engl J Med 1994;330:337-42.
3. Parsons SL, Watson SA, Steele RJ. Malignant ascites [Review]. Br J Surg 1996;83:6-14.
4. Runyon BA, Hoefs JC, Morgan TR. Ascitic fluid analysis in malignancy-related ascites. Hepatology 1988;8:1104-9.
5. Creasman WT, Rutledge F. The prognostic value of peritoneal cytology in gynecologic malignant disease. Am J Obstet Gynecol 1971;110:773-81.
6. Tobias JS, Griffiths CT. Management of ovarian carcinoma. N Engl J Med 1976;294:818-23.
7. Motherby H, Nadjari B, Friegel P, Kohaus J, Ramp U, Böcking A, et al. Diagnostic accuracy of effusion cytology. Diagn Cytopathol 1999;20:350-7.
8. Ayantunde AA, Parsons SL. Pattern and prognostic factors in patients with malignant ascites: A retrospective study. Ann Oncol 2007;18:945-9.
9. Spratt JS, Edwards M, Kubota T, Lindberg R, Tseng MT. Peritoneal carcinomatosis: Anatomy, physiology, diagnosis, management. Curr Probl Cancer 1986;10:558-84.
10. Moore KP, Wong F, Gines P, Bernardi M, Ochs A, Salerno F, et al. The management of ascites in cirrhosis: Report on the consensus conference of the international ascites club. Hepatology 2003;38:258-66.
11. Arroyo V, Ginès P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International ascites club. Hepatology 1996;23:164-76.
12. Cattau EL Jr., Benjamin SB, Knuff TE, Castell DO. The accuracy of the physical examination in the diagnosis of suspected ascites. JAMA 1982;247:1164-6.
13. Paola P, Rachel Z, David S, Theresa N. Molecular analysis of peritoneal fluid in ovarian cancer patients. Mod Pathol 2003;16:636-40.
14. Tarn AC, Lapworth R. Biochemical analysis of pleural fluid: What should we measure? Ann Clin Biochem 2001;38:311-22.
15. Paddock FK. The diagnostic significance of serous fluids in disease. N Engl J Med 1940;223:1010-5.
16. Rovelstad RA, Bartholomew LG, Cain JC, McKenzie BF, Soule EH. Ascites. I. The value of examination of ascitic fluid and blood for lipids and for proteins by electrophoresis. Gastroenterology 1958;34:436-51.
17. Boyer TD, Kahn AM, Reynolds TB. Diagnostic value of ascitic fluid lactic dehydrogenase, protein, and WBC levels. Arch Intern Med 1978;138:1103-5.
18. Runyon BA, Montano AA, Akriviadis EA, Antillon MR, Irving MA, McHutchison JG, et al. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann Intern Med 1992;117:215-20.
19. Maiya M. Diagnosis of Ascites-Pearls and Pitfalls. Available from: http://www.apiindia.org/pdf/medicine_update_2011/67_diagnosis_of_ ascites.pdf. [Last accessed on 2017 Oct 01].
20. Banerjee M, Singh R, Arora MM, Srinivas V, Basannar D, Parikar S. Biomarkers of malignant ascites-a myth or reality. Med J Armed Forces India 2011;67:108-12.
21. Understanding CA 125 Levels: A Guide for Ovarian Cancer Patients. Available from: http://www.foundationforwomenscancer.org/wp-content/uploads/CA125levels.pdf. [Last accessed on 2017 Oct 01].
22. Yedema CA, Kenemans P, Wobbes T, Thomas CM, Bon GG, Mulder C, et al. Use of serum tumor markers in the differential diagnosis between ovarian and colorectal adenocarcinomas. Tumor Biol 1992;13:18-26.
23. Bhaskari J, Krishnamoorthy L. Impact of ascites and plasma levels of VEGF-A in epithelial ovarian cancers. J Clin Cell Immunol 2015;6:1000353.
24. Lindsay AJ, Burton J, Ray CE Jr. Paracentesis-induced circulatory dysfunction: A primer for the interventional radiologist. Semin Intervent Radiol 2014;31:276-8.
25. Sola-Vera J, Miñana J, Ricart E, Planella M, González B, Torras X, et al. Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. Hepatology 2003;37:1147-53.
26. Goldberg BB, Goodman GA, Clearfield HR. Evaluation of ascites by ultrasound. Radiology 1970;96:1522.
27. Sood R. Ascites: Diagnosis and Management. Available from: http:// www.medind.nic.in/jac/t00/i1/jact00i1p81.pdf. [Last assessed on 2017 Oct 01].
28. Kozaki K, Takagi T, Fukuda T, Sanpei T, Terunuma Y, Yatabe Y, et al. Safety and effectiveness of cell-free concentrated ascites reinfusion therapy in gastric cancer patients with refractory ascites. Anat Physiol 2017;7:S6.
29. Thuluvath PJ, Bal JS, Mitchell S, Lund G, Venbrux A. TIPS for management of refractory ascites response and survival are both unpredictable. Dig Dis Sci 2003;48:542.
30. Runyon BA. Ascites and spontaneous bacterial peritonitis. In: Feldman M, Friedman LS, Brandt LJ, editors. Sleisenger and Fordtran’s Gastrointestinal and Liver Disease. 9th ed. Philadelphia, PA: Saunders Elsevier; 2010. p. 1517-41.
31. Angeli P, Dalla Pria M, De Bei E, Albino G, Caregaro L, Merkel C, et al. Randomized clinical study of the efficacy of amiloride and potassium canrenoate in nonazotemic cirrhotic patients with ascites. Hepatology 1994;19:72-9.
32. Ginsberg DJ, Saad A, Gabuzda GJ. Metabolic studies with the diuretic triamterene in patients with cirrhosis and ascites. N Engl J Med 1964;271:1229-35.
33. Hillenbrand P, Sherlock S. Use of metolazone in the treatment of ascites due to liver disease. Br Med J 1971;4:266-70.
34. McHutchison JG, Pinto PC, Reynolds TB. Hydrochlorothiazide as a third diuretic in cirrhosis with refractory ascites. Hepatology 1989;10:719.
35. Singh V, Dhungana SP, Singh B, Vijayverghia R, Nain CK, Sharma N, et al. Midodrine in patients with cirrhosis and refractory ascites: A randomized pilot study. J Hepatol 2012;56:348-54.
36. Fernandez J, Acevedo J, Castro M, Orlando G, Carlos R, Daria R, et al. Prevalence and risk factors of infections by resistant bacteria in cirrhosis: A prospective study. Hepatology 2012;55:1551-61.
37. Rongey C, Lim NH, Runyon BA. Cellulitis in patients with cirrhosis and edema: An under-recognized complication currently more common that spontaneous bacterial peritonitis. Open Gastro J 2008;2:24-7.
38. Soriano G, Guarner C, TeixidoM, Such J, Barrios J, Enriquez J, et al. Selective intestinal decontamination prevents spontaneous bacterial peritonitis. Gastroenterology 1991;100:477-81.
39. Gines P, Rimola A, Planas R, Vargas V, Marco F, Almela M, et al.Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: Results of a double-blind, placebo-controlled trial. Hepatology 1990;12:716-24.
40. Singh N, Gayowski T, Yu VL, Wagener MM. Trimethoprim-sulfamethoxazole for the prevention of spontaneous bacterial peritonitis in cirrhosis: A randomized trial. Ann Intern Med 1995;122:595-8.
41. Rolachon A, Cordier L, Bacq Y, Nousbaum JB, Franza A, Paris JC, et al. Ciprofloxacin and long-term prevention of spontaneous bacterial peritonitis: Results of a prospective controlled trial. Hepatology 1995;22:1171-4.
42. Fernández J, Navasa M, Planas R, Montoliu S, Monfort D, Soriano G, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007;133:818-24.
43. Saab S, Hernandez JC, Chi AC, Tong MJ. Oral antibiotic prophylaxis reduces spontaneous bacterial peritonitis occurrence and improves short-term survival in cirrhosis: A meta-analysis. Am J Gastroenterol 2009;104:993-1001.
44. Loomba R, Wesley R, Bain A, Csako G, Pucino F. Role of fluoroquinolones in the primary prophylaxis of spontaneous bacterial peritonitis: Meta-analysis. Clin Gastroenterol Hepatol 2009;7:487-93.
45. Felisart J, Rimola A, Arroyo V, Perez-Ayuso RM, Quintero E, Gines P, et al. Randomized comparative study of efficacy and nephrotoxicity of ampicillin plus tobramycin versus cefotaxime in cirrhotics with severe infections. Hepatology 1985;5:457-62.
46. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czewiec FS, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist for hyponatremia. N Engl J Med 2006;355:2099-112.
47. Cardenas A, Gines P, Marotta P, Czerwiec F, Oyuang J, Guevara M, et al. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. J Hepatol 2012;56:571-78.
48. Wong F, Watson H, Gerbes A, Vilstrup H, Badalamenti S, Bernardi M, et al. Satavaptan for the management of ascites in cirrhosis: Efficacy and safety across the spectrum of ascites severity. Gut 2012;61:108-16.
49. Constantin AD, Thomas JH, Doru TA, Carboplatin-gemcitabine in the therapy of advanced ovarian cancer: Dose reduction consideration. J Oncol Pharm Pract 2010;16:63-6.
50. Potamianou A, Androulakis N, Papakotoulas P, Toufexi H, Latoufis C, Kouroussis C, et al. Sequential combination of paclitaxel-carboplatin and paclitaxel-liposomal doxorubicin as a first-line treatment in patients with ovarian cancer. A multicenter phase II trial. Oncology 2005;69:348-53.
51. Pariente EA, Bataille C, Bercoff E, Lebrec D. Acute effects of catopril on systemic hemodynamics and on renal function in cirrhotic patients with ascites. Gastroenterology 1985;88:1255-9.
52. Gines P, Angeli P, Lenz K, Moller S, Moore K, Moreau R. EASL clinical practice guideline on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome. J Hepatol 2010;53:397-417.
53. Serste T, Melot C, Francoz C, Durand F, Rautou PE, Valla D, et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology 2010;52:1017-22.
54. Serste T, Francoz C, Durand F, Rautou PE, Melot C, Valla D, et al. Beta-blockers cause paracentesis induced circulatory dysfunction in patients with cirrhosis and refractory ascites: A cross-over study. J Hepatol 2011;55:794-9.
55. Srilatha M, Santhi R, Annapurani S. Anticancer activity of plant protein against Dalton’s lymphoma ascites tumor cell lines. Asian J Pharm Clin Res 2017;10:206-10.
56. Sujana N, Ramanathan S, Vimala V, Muthuraman MS, Pemaiah B. Antitumour potential of Passiflora Incarnata.L against Ehrlich ascites carcinoma. Int J Pharm Sci 2012;4:17-20.
137 Views | 169 Downloads
How to Cite
Singh, N., S. Patyar, and N. Chandra Talniya. “A COMPREHENSIVE INFORMATIVE NOTE ON ASCITES”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 11, no. 4, Apr. 2018, pp. 154-9, doi:10.22159/ajpcr.2018.v11i4.22948.
Original Article(s)